Cognition Therapeutics, Inc. announced a securities purchase agreement for 14,700,000 shares of common stock in a registered direct offering, expecting gross proceeds of about $30 million. The offering was made to two new fundamental institutional investors and will fund Phase 3 programs of zervimesine in neurodegenerative disorders. Titan Partners Group is the sole placement agent for the offering. The offering is being made pursuant to a shelf registration statement on Form S-3 and is expected to close on August 29, 2025. The Company is focused on developing drugs that treat neurodegenerative disorders and aims to regulate pathways impaired in these diseases.

Read more at GlobeNewswire: Cognition Therapeutics Announces $30 Million Registered